Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from AdAlta Ltd. ( (AU:1AD) ).
AdAlta Ltd has announced a change in the director’s interest, specifically concerning David Fuller. The change involves the disposal of 136,706 ordinary shares and 68,353 listed options by Fuller, resulting in a new holding of 491,560 ordinary shares and 98,312 listed options. This administrative correction of director allocation reflects a strategic adjustment in the company’s governance and may impact stakeholder perceptions of AdAlta’s financial and operational strategies.
More about AdAlta Ltd.
AdAlta Ltd is a biotechnology company focused on the development of novel therapeutic products. The company is known for its proprietary i-body technology, which is used to create new drugs for a range of diseases, including cancer and fibrosis.
Average Trading Volume: 1,060,063
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$2.52M
See more insights into 1AD stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue